FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2055123722> ?p ?o ?g. }

• W2055123722 endingPage "e30123" @default.
• W2055123722 startingPage "e30123" @default.
• W2055123722 abstract "Fatigue is a major cause of disability in primary Sjögren's syndrome (pSS). Fatigue has similarities with sickness behaviour in animals; the latter mediated by pro-inflammatory cytokines, in particular interleukin (IL)-1, acting on neuronal brain cells. We hypothesised that IL-1 inhibition might improve fatigue in pSS patients; thus, we examined the effects and safety of an IL-1 receptor antagonist (anakinra) on fatigue.Twenty-six pSS patients participated in a double-blind, placebo-controlled parallel group study. Patients were randomised to receive either anakinra or a placebo for four weeks. Fatigue was evaluated by a fatigue visual analogue scale and the Fatigue Severity Scale. The primary outcome measure was a group-wise comparison of the fatigue scores at week 4, adjusted for baseline values. Secondary outcome measures included evaluation of laboratory results and safety. The proportion of patients in each group who experienced a 50% reduction in fatigue was regarded as a post-hoc outcome. All outcomes were measured at week 4.There was no significant difference between the groups in fatigue scores at week 4 compared to baseline after treatment with anakinra. However, six out of 12 patients on anakinra versus one out of 13 patients on the placebo reported a 50% reduction in fatigue VAS (p = 0.03). There were two serious adverse events in each group.This randomised, double-blind, placebo-controlled trial of IL-1 blockade did not find a significant reduction in fatigue in pSS in its primary endpoint. A 50% reduction in fatigue was analysed post-hoc, and significantly more patients on the active drug than on placebo reached this endpoint. Although not supported by the primary endpoint, this may indicate that IL-1 inhibition influences fatigue in patients with pSS.ClinicalTrials.gov NCT00683345." @default.
• W2055123722 created "2016-06-24" @default.
• W2055123722 creator A5027560734 @default.
• W2055123722 creator A5031143276 @default.
• W2055123722 creator A5047578930 @default.
• W2055123722 creator A5088785200 @default.
• W2055123722 date "2012-01-10" @default.
• W2055123722 modified "2023-10-05" @default.
• W2055123722 title "Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial" @default.
• W2055123722 cites W1515994079 @default.
• W2055123722 cites W1590018298 @default.
• W2055123722 cites W1919460336 @default.
• W2055123722 cites W1936249141 @default.
• W2055123722 cites W1967315497 @default.
• W2055123722 cites W1967342482 @default.
• W2055123722 cites W1981503311 @default.
• W2055123722 cites W1987856010 @default.
• W2055123722 cites W1993537924 @default.
• W2055123722 cites W2012029166 @default.
• W2055123722 cites W2025160108 @default.
• W2055123722 cites W2025841148 @default.
• W2055123722 cites W2030711090 @default.
• W2055123722 cites W2035121795 @default.
• W2055123722 cites W2046677201 @default.
• W2055123722 cites W2055671309 @default.
• W2055123722 cites W2064622089 @default.
• W2055123722 cites W2072016770 @default.
• W2055123722 cites W2074229539 @default.
• W2055123722 cites W2087658385 @default.
• W2055123722 cites W2089159998 @default.
• W2055123722 cites W2099808663 @default.
• W2055123722 cites W2108554603 @default.
• W2055123722 cites W2112389587 @default.
• W2055123722 cites W2114242035 @default.
• W2055123722 cites W2114351006 @default.
• W2055123722 cites W2114850377 @default.
• W2055123722 cites W2115871198 @default.
• W2055123722 cites W2126795224 @default.
• W2055123722 cites W2146736075 @default.
• W2055123722 cites W2162411149 @default.
• W2055123722 cites W2163259162 @default.
• W2055123722 cites W2164540037 @default.
• W2055123722 cites W2167385753 @default.
• W2055123722 cites W2168772512 @default.
• W2055123722 cites W2168911501 @default.
• W2055123722 doi "https://doi.org/10.1371/journal.pone.0030123" @default.
• W2055123722 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3254637" @default.
• W2055123722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22253903" @default.
• W2055123722 hasPublicationYear "2012" @default.
• W2055123722 type Work @default.
• W2055123722 sameAs 2055123722 @default.
• W2055123722 citedByCount "136" @default.
• W2055123722 countsByYear W20551237222012 @default.
• W2055123722 countsByYear W20551237222013 @default.
• W2055123722 countsByYear W20551237222014 @default.
• W2055123722 countsByYear W20551237222015 @default.
• W2055123722 countsByYear W20551237222016 @default.
• W2055123722 countsByYear W20551237222017 @default.
• W2055123722 countsByYear W20551237222018 @default.
• W2055123722 countsByYear W20551237222019 @default.
• W2055123722 countsByYear W20551237222020 @default.
• W2055123722 countsByYear W20551237222021 @default.
• W2055123722 countsByYear W20551237222022 @default.
• W2055123722 countsByYear W20551237222023 @default.
• W2055123722 crossrefType "journal-article" @default.
• W2055123722 hasAuthorship W2055123722A5027560734 @default.
• W2055123722 hasAuthorship W2055123722A5031143276 @default.
• W2055123722 hasAuthorship W2055123722A5047578930 @default.
• W2055123722 hasAuthorship W2055123722A5088785200 @default.
• W2055123722 hasBestOaLocation W20551237221 @default.
• W2055123722 hasConcept C126322002 @default.
• W2055123722 hasConcept C14184104 @default.
• W2055123722 hasConcept C142724271 @default.
• W2055123722 hasConcept C168563851 @default.
• W2055123722 hasConcept C1862650 @default.
• W2055123722 hasConcept C197934379 @default.
• W2055123722 hasConcept C202061045 @default.
• W2055123722 hasConcept C203092338 @default.
• W2055123722 hasConcept C204787440 @default.
• W2055123722 hasConcept C27081682 @default.
• W2055123722 hasConcept C2779134260 @default.
• W2055123722 hasConcept C2779566273 @default.
• W2055123722 hasConcept C2781228260 @default.
• W2055123722 hasConcept C2991744798 @default.
• W2055123722 hasConcept C71924100 @default.
• W2055123722 hasConceptScore W2055123722C126322002 @default.
• W2055123722 hasConceptScore W2055123722C14184104 @default.
• W2055123722 hasConceptScore W2055123722C142724271 @default.
• W2055123722 hasConceptScore W2055123722C168563851 @default.
• W2055123722 hasConceptScore W2055123722C1862650 @default.
• W2055123722 hasConceptScore W2055123722C197934379 @default.
• W2055123722 hasConceptScore W2055123722C202061045 @default.
• W2055123722 hasConceptScore W2055123722C203092338 @default.
• W2055123722 hasConceptScore W2055123722C204787440 @default.
• W2055123722 hasConceptScore W2055123722C27081682 @default.
• W2055123722 hasConceptScore W2055123722C2779134260 @default.
• W2055123722 hasConceptScore W2055123722C2779566273 @default.
• W2055123722 hasConceptScore W2055123722C2781228260 @default.

• next